Skip to content
drillr.ai
Sign up

300357.SZ

我武生物

SZSE · Healthcare · C 制造业 · CN

CNY 23.26
−5.64%
Ask drillr

  • Aug 27, 2026, 10:29 UTC

    Wolwo Bio-Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders of 213 million yuan, up 20.59% year-on-year.

    Source:

  • Aug 21, 2026, 09:10 UTC

    China's National Medical Products Administration approved Wolwo Bio-Pharmaceutical's clinical trial application for its cat dander membrane agent, a Class 1 therapeutic biological product, for allergic rhinitis related to cat dander sensitization.

    Source: